Evaluation of immune response to orally administered Sterne strain 34F2 anthrax vaccine

Vaccine

Volumn 25, Issue 29, 2007, Pages 5374-5377

  Shakya, Krishna P ^a   Hugh Jones, Martin E ^a,b   Elzer, Philip H ^a,c  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY AGRICULTURAL CENTER   (United States)

Author keywords

Anthrax; Bacillus anthracis; Oral vaccine; Sterne strain 34F2

Indexed keywords

ANTHRAX VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOAT; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GOATS; IMMUNOGLOBULIN G; MODELS, ANIMAL;

EID: 34250861427     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.003     Document Type: Article

References (14)

1. Chabot D.J., Scorpio A., Tobery S.A., Little S.F., Norris S.L., and Friedlander A.M. Anthrax capsule vaccine protects against experimental infection. Vaccine 23 1 (2004) 43-47
2. Singh Y., Ivins B.E., and Leppla S.H. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect Immun 66 7 (1998) 3447-3448
3. Turnbull P.C. Anthrax vaccines: past, present and future. Vaccine 9 8 (1991) 533-539
4. Manufacturer's insert: Sterne strain 34F2 vaccine, Colorado Serum Co., Denver, CO.
5. Cartwright M.E., McChesney A.E., and Jones R.L. Vaccination-related anthrax in three llamas. J Am Vet Med Assoc 191 6 (1987) 715-716
6. Hugh-Jones M.E., and de Vos V. Anthrax and wildlife. Rev Sci Tech Off Int Epiz 21 2 (2002) 359-383
7. Edmonds M.D., Samartino L.E., Hoyt P.G., Hagius S.D., Walker J.V., Enright F.M., et al. Oral vaccination of sexually mature pigs with Brucella abortus vaccine strain RB51. Am J Vet Res 62 8 (2001) 1328-1331
8. Alileche A., Serfass E.R., Muehlbauer S.M., Porcelli S.A., and Brojatsch J. Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLoS Pathog 1 2 (2005) e19
9. Mohamed N., Li J., Ferreira C.S., Little S.F., Friedlander A.M., Spitalny G.L., et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun 72 6 (2004) 3276-3283
10. Hanson J.F., Taft S.C., and Weiss A.A. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol 13 2 (2006) 208-213
11. Ivins B.E., Fellows P.F., and Nelson G.O. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 12 10 (1994) 872-874
12. Aloni-Grinstein R., Gat O., Altboum Z., Velan B., Cohen S., and Shafferman A. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 73 7 (2005) 4043-4053
13. Little S.F., and Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 2 (1986) 509-512
14. Mikshis N.I., Korsakova A., Bolotnikova M.F., Novikova L.V., and Popov Iu A. Role of the components of the S-layer in immunogenicity of Bacillus anthracis. Zh Mikrobiol Epidemiol Immunobiol 1 (2006) 29-32